




RealRate

PHARMACEUTICAL 2022

Neximmune Inc
Rank 148 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Neximmune Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Neximmune Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 95% points. The greatest weakness of Neximmune Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 28% points.

The company's Economic Capital Ratio, given in the ranking table, is 347%, being 72% points above the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	86,281
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,216
Liabilities, Non-Current	0
Other Assets	324
Other Compr. Net Income	3.0
Other Expenses	0
Other Liabilities	56
Other Net Income	2,354
Other Revenues	0
Property and Equipment	4,427
Research and Development	37,456
Selling, General and Administrative Expense	15,799

Output Variable	Value in 1000 USD
Assets	91,032
Liabilities	7,271
Expenses	53,256
Revenues	0
Stockholders Equity	83,761
Net Income	-50,902
Comprehensive Net Income	-50,900
BaseVar	76,958
ECR before Limited Liability	268%
Economic Capital Ratio	347%